The most successful way and major goal for treating Alzheimer's disease is to diminish acetylcholine levels by using transitory inhibitors to block the cholinesterase that AChE and BuChE catalyze (Sang et al., 2022). This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.